Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
Neural Regulation01:37

Neural Regulation

40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biochemical Regulation of Brain Kynurenic Acid Synthesis and Inhibition in Rats Is Sensitive to the Time of Day.

ACS chemical neuroscience·2026
Same author

Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.

bioRxiv : the preprint server for biology·2025
Same author

Uncovering synaptic and cellular nanoarchitecture of brain tissue via seamless <i>in situ</i> trimming and milling for cryo-electron tomography.

bioRxiv : the preprint server for biology·2025
Same author

Aging disrupts the coordination between mRNA and protein expression in mouse and human midbrain.

bioRxiv : the preprint server for biology·2024
Same author

A blood-based marker of mitochondrial DNA damage in Parkinson's disease.

Science translational medicine·2023
Same author

Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration.

Aging cell·2021

Related Experiment Video

Updated: Sep 20, 2025

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.7K

LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.

Silas A Buck1,2, Laurie H Sanders1,2

  • 1Departments of Neurology and Pathology, Duke University School of Medicine, Durham, NC 27710, U.S.A.

The Biochemical Journal
|May 29, 2025
PubMed
Summary

Parkinson's disease (PD) involves dopamine neuron loss. Leucine-rich repeat kinase 2 (LRRK2) mutations, linked to PD, may cause neuron degeneration through mitochondrial dysfunction.

Keywords:
LRRK2Parkinson’s diseasemitochondriamitochondrial DNAmitophagy

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

15.4K

Related Experiment Videos

Last Updated: Sep 20, 2025

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.7K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

15.4K

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder affecting dopamine neurons.
  • Familial PD cases are often linked to genetic mutations, with leucine-rich repeat kinase 2 (LRRK2) being a common cause.
  • Pathogenic LRRK2 mutations elevate its kinase activity, but the precise mechanisms leading to neuron degeneration remain unclear.

Purpose of the Study:

  • To review the current understanding of LRRK2's role in mitochondrial dysfunction in Parkinson's disease.
  • To explore how LRRK2 impacts mitochondrial energetics, oxidative stress, and other cellular processes relevant to PD.
  • To examine LRRK2's potential role in mediating the effects of emerging mitochondrial therapeutics for PD.

Main Methods:

  • Literature review of studies investigating LRRK2 and mitochondrial function in Parkinson's disease.
  • Analysis of research connecting LRRK2 mutations to mitochondrial energetics, oxidative stress, genome integrity, fission/fusion dynamics, mitophagy, and transport.
  • Synthesis of evidence regarding LRRK2's influence on mitochondrial health and its implications for PD pathogenesis.

Main Results:

  • Growing evidence links pathogenic LRRK2 mutations to various aspects of mitochondrial dysfunction.
  • LRRK2 appears to influence mitochondrial energetics, oxidative stress, mitochondrial dynamics, and mitophagy.
  • These LRRK2-mediated mitochondrial effects are increasingly recognized as critical contributors to dopamine neuron degeneration in PD.

Conclusions:

  • LRRK2 plays a significant role in mitochondrial dysfunction, a key factor in Parkinson's disease pathogenesis.
  • Understanding LRRK2's impact on mitochondria offers potential therapeutic targets for PD.
  • LRRK2 may influence the efficacy of mitochondrial therapeutics currently under investigation for Parkinson's disease.